All data are based on the daily closing price as of September 1, 2025
s
Sunmax Biotechnology
4728.TWO
13.33 USD
-0.03
-0.22%
Overview
Last close
13.33 usd
Market cap
725.82M usd
52 week high
16.58 usd
52 week low
6.37 usd
Target price
N/A usd
Valuation
P/E
31.9672
Forward P/E
N/A
Price/Sales
11.4313
Price/Book Value
17.8562
Enterprise Value
690.36M usd
EV/Revenue
19.5273
EV/EBITDA
22.6967
Key financials
Revenue TTM
63.74M usd
Gross Profit TTM
50.65M usd
EBITDA TTM
33.64M usd
Earnings per Share
0.42 usd
Dividend
0.38 usd
Total assets
81.75M usd
Net debt
N/A usd
About
Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets collagen-based medical devices in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax FACIALGAIN collagen implant with lidocaine, Sunmax collagen implant I-Plus, Sumax collagen implant I, Sunmax FACIALGAIN collagen implant 1-Plus with lidocaine for the correction of facial defects, such as the fill up of wrinkles; and Porcogen, a sterile purified collagen solution for medical device, tissue engineering, and research purposes. It also provides Sunmax collagen dental bone graft, Sunmax collagen dental membrane, and Sunmax dental bone graft granules, which are used in the augmentation or reconstructive treatment of the alveolar ridge. In addition, the company offers Sunmax collagen bone graft matrix that provides a bone void filler that is resorbed and replaced with bone during the healing process; and skincare products comprising Sunmax 12 jiao didi spray, Sunmax 11 collagen moisturizing cream, and Sunmax collagen skincare that are used as aftercare of dermal filler treatment. Sunmax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Tainan City, Taiwan.